CATX

Perspective Therapeutics Inc

Add to Watchlist

Advanced Chart

2.420

+0.070(+2.980%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.450

Open

2.350

VWAP

2.39

Vol

557.33K

Mkt Cap

179.20M

Low

2.270

Amount

1.33M

EV/EBITDA(TTM)

Total Shares

67.41M

-51.22M

EV/OCF(TTM)

P/S(TTM)

104.09

Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

123.91K

-66.42%

123.17K

-76.58%

143.93K

-55.71%

Estimates Revision

The market is revising Downward the revenue expectations for Perspective Therapeutics, Inc. (CATX) for FY2025, with the revenue forecasts being adjusted by -14.24% over the past three months. During the same period, the stock price has changed by -25.31%.

Revenue Estimates for FY2025

Revise Downward

-14.24%

In Past 3 Month

Stock Price

Go Down

-25.31%

In Past 3 Month

10 Analyst Rating

460.33% Upside

Wall Street analysts forecast CATX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CATX is 13.56 USD with a low forecast of 6.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

460.33% Upside

Current: 2.420

Low

6.00

Averages

13.56

High

21.00

460.33% Upside

Current: 2.420

Low

6.00

Averages

13.56

High

21.00

Truist Securities

Nicole Germino

Strong Buy

Maintains

$21 → $10

2025-04-07

Reason

Truist Securities

Nicole Germino

Price Target

$21 → $10

2025-04-07

Maintains

Strong Buy

Reason

Truist lowered the firm's price target on Perspective Therapeutics to $10 from $21 and keeps a Buy rating on the shares. Based on its discussions with the management, the firm has adjusted its model's launch curve timelines for the company's lead assets to reflect the pace of the dose escalation trials for two clinical programs, the analyst tells investors in a research note.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$10

2025-03-31

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10

2025-03-31

Reiterates

Strong Buy

Reason

Wedbush

David Nierengarten

Buy

Reiterates

$11

2025-03-27

Reason

Wedbush

David Nierengarten

Price Target

$11

2025-03-27

Reiterates

Buy

Reason

RBC Capital

Gregory Renza

Buy

Maintains

$16 → $15

2025-03-27

Reason

RBC Capital

Gregory Renza

Price Target

$16 → $15

2025-03-27

Maintains

Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$10

2025-03-19

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10

2025-03-19

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Initiates

$10

2025-03-13

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10

2025-03-13

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Perspective Therapeutics Inc (CATX.A) is -1.86, compared to its 5-year average forward P/E of -14.75. For a more detailed relative valuation and DCF analysis to assess Perspective Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-14.75

Current PE

-1.86

Overvalued PE

2.83

Undervalued PE

-32.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.61

Current EV/EBITDA

0.66

Overvalued EV/EBITDA

6.23

Undervalued EV/EBITDA

-19.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

186.08

Current PS

248.30

Overvalued PS

689.79

Undervalued PS

-317.64

Financials

Annual

Quarterly

FY2024Q4

234.00K

Total Revenue

FY2024Q4

-20.90M

Operating Profit

FY2024Q4

-40.17M

Net Income after Tax

FY2024Q4

-0.57

EPS - Diluted

FY2024Q4

YoY :

+353.64%

-41.27M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

+88.88%

-5.01K

FCF Margin - %

FY2024Q4

YoY :

+557.23%

-17.17K

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 951.27% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

316.8K

USD

Months

3-6

30.1K

USD

Months

6-9

172.3K

USD

Months

0-12

235.1K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.8M

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.3M

Volume

Months

6-9

0.0

Volume

Months

0-12

13.5M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 951.27% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

316.8K

USD

Months

3-6

30.1K

USD

Months

6-9

172.3K

USD

Months

0-12

235.1K

USD

Months

CATX News & Events

Events Timeline

2025-04-29 (ET)

2025-04-29

07:16:26

Perspective Therapeutics announces first patient dosed with PSV359

2025-04-11 (ET)

2025-04-11

07:02:18

Perspective announces first patient dosed in Phase 1/2a trial of 212PbVMT01

2025-03-17 (ET)

2025-03-17

07:14:08

Perspective Therapeutics says first patient dosed in Phase 1/2a trial of VMT01

News

9.0

04-29Yahoo Finance

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

9.0

04-23Newsfilter

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

6.5

04-14TipRanks

Tax Day 2025 IRS Payment: Stocks to Consider Buying With the Refund

People Also Watch

TBN

Tamboran Resources Corp

Security National Financial Corp

Postal Realty Trust Inc

Vishay Precision Group Inc

FAQ

What is Perspective Therapeutics Inc (CATX) stock price today?

The current price of CATX is 2.42 USD — it has increased 2.98 % in the last trading day.

CATX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CATX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Perspective Therapeutics Inc (CATX) stock price today?

What is Perspective Therapeutics Inc (CATX)'s business?

What is the price predicton of CATX Stock?

What is Perspective Therapeutics Inc (CATX)'s revenue for the last quarter?

What is Perspective Therapeutics Inc (CATX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Perspective Therapeutics Inc (CATX)'s fundamentals?

How many employees does Perspective Therapeutics Inc (CATX). have?

What is Perspective Therapeutics Inc (CATX) market cap?